65.36
-2.11 (-3.13%)
| Previous Close | 67.47 |
| Open | 66.95 |
| Volume | 1,284,854 |
| Avg. Volume (3M) | 2,573,054 |
| Market Cap | 8,150,774,784 |
| Price / Sales | 9.17 |
| Price / Book | 55.67 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | -53.82% |
| Operating Margin (TTM) | -54.33% |
| Diluted EPS (TTM) | -3.39 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -272.26 M |
| Levered Free Cash Flow (TTM) | -67.71 M |
| Return on Assets (TTM) | -18.64% |
| Return on Equity (TTM) | -4,584.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Guardant Health, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.13 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 4.53% |
| % Held by Institutions | 97.57% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cadian Capital Management, Lp | 30 Jun 2025 | 3,179,217 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (UBS, 22.40%) | Buy |
| 80.00 (BTIG, 22.40%) | Buy | |
| Median | 70.00 (7.10%) | |
| Low | 60.00 (Scotiabank, -8.20%) | Buy |
| Average | 71.00 (8.63%) | |
| Total | 15 Buy | |
| Avg. Price @ Call | 57.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 07 Oct 2025 | 68.00 (4.04%) | Buy | 63.44 |
| Barclays | 02 Oct 2025 | 70.00 (7.10%) | Buy | 61.46 |
| Canaccord Genuity | 26 Sep 2025 | 75.00 (14.75%) | Buy | 60.03 |
| BTIG | 25 Sep 2025 | 80.00 (22.40%) | Buy | 60.18 |
| 22 Sep 2025 | 70.00 (7.10%) | Buy | 59.78 | |
| Guggenheim | 25 Sep 2025 | 67.00 (2.51%) | Buy | 60.18 |
| JP Morgan | 25 Sep 2025 | 70.00 (7.10%) | Buy | 60.18 |
| Leerink Partners | 25 Sep 2025 | 75.00 (14.75%) | Buy | 60.18 |
| Mizuho | 25 Sep 2025 | 70.00 (7.10%) | Buy | 60.18 |
| Stifel | 25 Sep 2025 | 70.00 (7.10%) | Buy | 60.18 |
| TD Cowen | 25 Sep 2025 | 72.00 (10.16%) | Buy | 60.18 |
| UBS | 25 Sep 2025 | 80.00 (22.40%) | Buy | 60.18 |
| Wolfe Research | 25 Sep 2025 | 75.00 (14.75%) | Buy | 60.18 |
| Wells Fargo | 22 Sep 2025 | 72.00 (10.16%) | Buy | 59.78 |
| Raymond James | 31 Jul 2025 | 61.00 (-6.67%) | Buy | 40.98 |
| Scotiabank | 31 Jul 2025 | 60.00 (-8.20%) | Buy | 40.98 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |